TriNetX and Fujitsu Launch Joint Venture to Increase Japanese Patients’ Access to Life-Changing Medicines
Partnership taps real-world data to accelerate clinical trials, research, and drug development…
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
– GOMEKLI is the first and only medicine approved for both adults…
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
– GOMEKLI is the first and only medicine approved for both adults…
ZIWIG ENDOTEST: FAST-TRACK REIMBURSEMENT FOR 25 000 PATIENTS FOR FIRST SALIVA TEST TO DIAGNOSE ENDOMETRIOSIS IN 80 MEDICAL CENTERS IN FRANCE
LYON, France, Feb. 11, 2025 /PRNewswire/ -- Ziwig, a French biotech company committed…
Philips, World Bank, and Ukraine Ministry of Health announce successful deployment of nationwide acute stroke care upgrade, helping thousands of patients
February 10, 2025 Groundbreaking program that provides technology and training is reducing…
EYLEA HD (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior…
Three-Year Results for EYLEA HD (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals
At three years of EYLEA HD treatment, the vast majority of patients…
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trialin Patients with Idiopathic Pulmonary Fibrosis
February 07, 2025 16:58 ET | Source: Pliant Therapeutics, Inc. Following DSMB…
Corti’s First AId Report: Burnout levels challenge healthcare professionals’ ability to care for patients in Europe and the U.S.
Artificial Intelligence could be a lifeline but unsuccessful trials, limited opportunities, and…
Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor…